Clinical and electrophysiologic assessment of oral flecainide acetate for recurrent ventricular tachycardia: Evidence for exacerbation of electrical instability
Authors:
- William J. OetgenWOWilliam J. Oetgen
- Paul A. TibbitsPTPaul A. Tibbits
- Mary E.O. AbtMAMary E.O. Abt
- Robert E. GoldsteinRGRobert E. Goldstein
- 1 October 1983
- journal article
- research article
- Published by Elsevier in The American Journal of Cardiology
- Vol. 52 (7) , 746-750
Abstract
No abstract availableKeywords
This publication has 7 references indexed in Scilit:
- Flecainide-induced QT prolongation and ventricular tachycardiaAmerican Heart Journal, 1982
- Programmed ventricular stimulation in predicting vulnerability to ventricular arrhythmias and their response to antiarrhythmic therapyAmerican Heart Journal, 1982
- Suppression of resistant ventricular arrhythmias by twice daily dosing with flecainideThe American Journal of Cardiology, 1981
- Malignant ventricular tachyarrhythmias associated with the use of encainideAmerican Heart Journal, 1981
- Oral Flecainide Acetate for the Treatment of Ventricular ArrhythmiasNew England Journal of Medicine, 1981
- Flecainide acetate, a new antiarrhythmic agent: Dose-ranging and efficacy studyThe American Journal of Cardiology, 1981
- Electrode-catheter arrhythmia induction in the selection and assessment of antiarrhythmic drug therapy for recurrent ventricular tachycardia.Circulation, 1978